VF
MGX icon

Virtu Financial’s Metagenomi Therapeutics MGX Stock Holding History

Virtu Financial’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,008
Closed -$28K – 2186
2025
Q2 		$28K Sell
19,008
-12,650
-40% -$19.8K ﹤0.01% 1216
2025
Q1 		$43K Buy
+31,658
New +$75.4K ﹤0.01% 1029
2024
Q4 		– Sell
-15,263
Closed -$33K – 2157
2024
Q3 		$33K Buy
+15,263
New +$53K ﹤0.01% 1067

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Virtu Financial's MGX Position: Q3 2025 in Review

Virtu Financial sold out of Metagenomi Therapeutics (MGX) in Q3 2025, closing a stake of 19,008 shares — an estimated $28K sold.

Virtu Financial first reported a position in MGX in Q3 2024 and held it in 3 quarters. The position peaked at $43K in Q1 2025. 58 funds tracked by Wall St. Rank hold MGX as of Q3 2025.

  • Virtu Financial reported no remaining Metagenomi Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Virtu Financial sold 19,008 Metagenomi Therapeutics shares in Q3 2025, an estimated $28K.
  • Virtu Financial first reported a position in Metagenomi Therapeutics in Q3 2024 and held it in 3 quarters.
  • Virtu Financial's Metagenomi Therapeutics position peaked at $43K in Q1 2025.
  • 58 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2025.

Based on Virtu Financial's 13F filing for Q3 2025, filed 14 Nov 2025.